Integrated analyses of transcriptional and non-transcriptional genes regulated by telmisartan identified cross-talk between the angiotensin-PPAR-NFκB signaling pathways, which could have contributed to the pharmacological effects of telmisartan on NASH. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.